Cited 0 times in
Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn's Disease: A Multicenter Observational Study
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김태일 | - |
dc.contributor.author | 박수정 | - |
dc.contributor.author | 박재준 | - |
dc.contributor.author | 박지혜 | - |
dc.contributor.author | 천재영 | - |
dc.contributor.author | 천재희 | - |
dc.date.accessioned | 2024-05-23T03:25:13Z | - |
dc.date.available | 2024-05-23T03:25:13Z | - |
dc.date.issued | 2024-03 | - |
dc.identifier.issn | 0163-2116 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/199221 | - |
dc.description.abstract | Background: Methotrexate (MTX) combination therapy with biological agents has gained increasing interest. Here, we assessed the efficacy and tolerability of the MTX combination therapy in patients with Crohn's disease (CD). Methods: We performed a multicenter observational study with 185 patients with CD with MTX and biologics combination therapy; the patients were recruited from three IBD Clinics in Korea. We evaluated the outcomes of the MTX combination therapy and examined the predictive factors of clinical and endoscopic remission. Results: MTX was administered orally to 62.7% of patients; the mean dose was 15.5 mg per week, and the mean treatment duration was 36 months. Of the 169 patients treated with MTX combination therapy for over 6 months, the steroid-free clinical remission rates were 34.3%, 26.0%, 29.8%, and 32.7% at 4, 12, 18, and 24 months, respectively. Previous thiopurine use was a significant negatively associated independent factor (p < 0.001), and a higher dose of MTX (≥ 15 mg/week) was a positively associated independent factor of steroid-free clinical remission (p = 0.035). Ninety-six patients underwent follow-up endoscopy after 28 months, and 36 (37.5%) achieved endoscopic remission. Longer disease duration (p = 0.006), ileocolonic type of Montreal location (p = 0.036), and baseline C-reactive protein (CRP) level of more than 5 mg/L (p = 0.035) were significant negatively associated independent factors and a higher dose of MTX (≥ 15 mg/week) was a positively associated independent factor of endoscopic remission (p = 0.037). Conclusions: MTX combination therapy with biologics was effective and tolerable in patients with CD. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Springer Science + Business Media | - |
dc.relation.isPartOf | DIGESTIVE DISEASES AND SCIENCES | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Biological Products* / therapeutic use | - |
dc.subject.MESH | Crohn Disease* / diagnosis | - |
dc.subject.MESH | Crohn Disease* / drug therapy | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Immunosuppressive Agents / therapeutic use | - |
dc.subject.MESH | Methotrexate / therapeutic use | - |
dc.subject.MESH | Remission Induction | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Effectiveness and Tolerability of Methotrexate Combined with Biologics in Patients with Crohn's Disease: A Multicenter Observational Study | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Jihye Park | - |
dc.contributor.googleauthor | Jaeyoung Chun | - |
dc.contributor.googleauthor | Soo Jung Park | - |
dc.contributor.googleauthor | Jae Jun Park | - |
dc.contributor.googleauthor | Tae Il Kim | - |
dc.contributor.googleauthor | Hyuk Yoon | - |
dc.contributor.googleauthor | Jae Hee Cheon | - |
dc.identifier.doi | 10.1007/s10620-023-08237-0 | - |
dc.contributor.localId | A01079 | - |
dc.contributor.localId | A01539 | - |
dc.contributor.localId | A01636 | - |
dc.contributor.localId | A04575 | - |
dc.contributor.localId | A05701 | - |
dc.contributor.localId | A04030 | - |
dc.relation.journalcode | J00737 | - |
dc.identifier.eissn | 1573-2568 | - |
dc.identifier.pmid | 38217678 | - |
dc.identifier.url | https://link.springer.com/article/10.1007/s10620-023-08237-0 | - |
dc.subject.keyword | Adverse reactions | - |
dc.subject.keyword | Combination therapy | - |
dc.subject.keyword | Crohn’s disease | - |
dc.subject.keyword | Drug-related side effects | - |
dc.subject.keyword | Methotrexate | - |
dc.subject.keyword | Treatment outcome | - |
dc.contributor.alternativeName | Kim, Tae Il | - |
dc.contributor.affiliatedAuthor | 김태일 | - |
dc.contributor.affiliatedAuthor | 박수정 | - |
dc.contributor.affiliatedAuthor | 박재준 | - |
dc.contributor.affiliatedAuthor | 박지혜 | - |
dc.contributor.affiliatedAuthor | 천재영 | - |
dc.contributor.affiliatedAuthor | 천재희 | - |
dc.citation.volume | 69 | - |
dc.citation.number | 3 | - |
dc.citation.startPage | 901 | - |
dc.citation.endPage | 910 | - |
dc.identifier.bibliographicCitation | DIGESTIVE DISEASES AND SCIENCES, Vol.69(3) : 901-910, 2024-03 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.